Compare Barrick Gold Corp (B) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs DexCom, Inc. — how do they compare? Barrick Gold Corp trades at $35.92 (market cap $60.50B), while DexCom, Inc. trades at $72.58 (market cap $28.60B). The key difference: Barrick Gold Corp is far larger — about 2.1× DexCom, Inc.'s market cap, and Barrick Gold Corp pays a 1.92% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| B | DXCM | |
|---|---|---|
Market Cap | $60.50B | $28.60B |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $89.53 |
52-Week Low | $20.73 | $54.84 |
Enterprise Value | $58.09B | $27.57B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $35.94, down 2.02% today, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and three consecutive quarterly EPS beats. Recent cash flow trends improved significantly, with 2025 net cash flow turning positive at $2.63 billion. The company announced a $0.18 dividend payable in June 2026.
The outlook remains positive given low valuation multiples, robust profitability, and analyst consensus of $52.67 price target. Key risks include gold price volatility and execution of growth projects. With 68% analyst buy ratings and no sell recommendations, Wall Street sentiment supports long-term upside potential despite near-term technical weakness.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
